Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads
The answer: it depends on what phase the trial is in.
Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Merck's CETP inhibitor anacetrapib and Novartis' monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.
This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug
FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena